Intelligent Bio Solutions

INBS

Market cap $6.24M

New York, New York--(Newsfile Corp. - November 20, 2025) - Intelligent Bio Solutions Inc. (NASDAQ: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in Noble Capital Markets' 21st Annual Emerging Growth Equity Conference, taking place over December 2-3, 2025, in Boca Raton, Florida. Conference Details Date: December 2-3, 2025 Location: Florida Atlantic University, Boca Raton, FL Presentation Date and Time: Wednesday, December 3, 2025, 11:00 a.m.

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in Noble Capital Markets' 21st Annual Emerging Growth Equity Conference, taking place over December 2-3, 2025, in Boca Raton, Florida.

Record quarterly revenue of $1.11 million, an increase of 32% sequentially and 28% year-over-year, driven by consumable cartridge sales and customer base expansion

C ompany Achieves Third Consecutive Quarter of Revenue Growth Revenue Increase of Approximately 32% Sequentially and 28% Year-Over-Year Driven by New Customer Accounts and Strong Cartridge and Reader Sales Cartridge and Reader Revenue Up Approximately 43% and 23% Year-Over-Year Respectively NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary, unaudited revenue results for the fiscal first quarter ended September 30, 2025.  “We started fiscal year 2026 on a strong note, generating over $1 million in revenue - a record for our Company and a significant milestone,” said Harry Simeonidis, President and CEO of Intelligent Bio Solutions.

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition of 33 new customer accounts during its fiscal first quarter for the period ended September 30, 2025, representing a 50% increase compared with the same period the prior year. The continued growth brings the Company's total number of active accounts to over 480, demonstrating sustained customer expansion and revenue momentum.

Multinational company employs approximately 3,000 staff within the UK and Ireland and more than 30,000 staff worldwide Large new customer account highlights accelerating adoption of the Company's rapid, non-invasive drug testing technology across high-volume, safety-critical sectors NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has secured a major new contract with one of the United Kingdom's largest industrial service providers. The multinational company, a global leader operating across the energy, defence, nuclear, and industrial sectors, employs more than 30,000 people worldwide and services complex, safety-critical projects across Europe, the Middle East, and Asia-Pacific.

The Company is initiating clinical studies to further validate Intelligent Fingerprinting Drug Screening System INBS anticipates FDA 510(k) clearance in the second half of 2026 NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today is providing an update on the timeline for anticipated FDA 510(k) clearance for the use of its Intelligent Fingerprinting Drug Screening System for the opiate codeine.

NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today provided an update on its FDA 510(k) clearance process for its Intelligent Fingerprinting Drug Screening System.

Company reports all-time-high monthly cartridge sales for July with 60% year-on-year growth Company reports all-time-high monthly cartridge sales for July with 60% year-on-year growth

Company advanced efforts to secure U.S. FDA 510(k) clearance to advance on path towards planned U.S. market expansion beyond Forensic Use Only settings